Mallinckrodt Pharmaceuticals is looking to divest its generic drug business, unnamed sources told Reuters.
Here are four things to know.
- Mallinckrodt hired investment bank Credit Suisse Group to launch a sales process for the generic drug unit, sources told Reuters Tuesday.
- The sources — who note the sales talks do not guarantee a divestiture — said a deal could be worth up to $2 billion, according to the report.
- The deal would align with Mallinckrodt's efforts to shift focus away from generics to its portfolio of branded specialty drugs, which generate the majority of its revenues, reports Reuters.
- Mallinckrodt and Credit Suisse declined Reuters' request for comment.
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Dr. Scott Gottlieb talks drug price strategies, FDA hiring freeze: 4 takeaways
Sawai Pharma to acquire Upsher-Smith's generic drug unit for $1B